Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

EarningsVK2735Positive

AI Analysis

Summary

Viking Therapeutics reported Q2 2026 financial results and announced full enrollment of Phase 3 VANQUISH 1 & 2 trials for subcutaneous VK2735 in obesity, with maintenance dosing data expected in Q3 2026 and oral Phase 3 trial initiation anticipated in Q4 2026.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Q2 2026 financial results reported; Phase 3 trials fully enrolled

Importance:7/10

Sentiment:

0.70

Phase 3VK2735ObesityTrial EnrollmentSubcutaneousOral FormulationMaintenance Dosing DataCorporate Update

Related Companies

$VKTX

Read the original article

Published by PR Newswire Clinical Trials on July 29, 2026 8:05 PM

Read Original